PROGNYX

Home/The Watchtower/AbbVie files FDA application for etentamig, its BCMA bisp…

Editorial illustration for the Prognyx briefing on etentamig, BCMA x CD3 bispecific antibody

Briefing · From the Watchtower

AbbVie files FDA application for etentamig, its BCMA bispecific for myeloma

AbbVie submitted a BLA on 27 October 2026 for etentamig in relapsed/refractory multiple myeloma, a class already served by three marketed bispecifics.

By · Founder, Prognyx ● Sourced to primary records Oncology
In brief: AbbVie submitted a Biologics License Application to the U.S. FDA on 27 October 2026 for etentamig, its second-generation BCMA x CD3 bispecific antibody T-cell engager given intravenously, for adults with relapsed or refractory multiple myeloma. The filing pushes etentamig toward a decision in an already-served BCMA-directed class that holds marketed T-cell-engaging bispecifics teclistamab, elranatamab and linvoseltamab, with AbbVie positioning the asset for use across a broad range of settings including community-based care.

AbbVie submitted a Biologics License Application to the U.S. FDA on 27 October 2026 for etentamig, a second-generation BCMA x CD3 bispecific antibody T-cell engager given intravenously, in adults with relapsed or refractory multiple myeloma [1]. The filing moves another T-cell engager toward a decision in a class the FDA has already labeled several times over.

What happened

AbbVie announced the submission on 27 October 2026 [1]. The company describes etentamig as having "a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, including in community-based care" [1]. That is the differentiation claim the operator should read: administration and site of care, in a class already established on efficacy.

Why it matters for competing programs

Etentamig would enter a BCMA-directed field with multiple FDA-labeled T-cell-engaging bispecifics on the books. Teclistamab (TECVAYLI) carries a label spanning from one prior line, in combination with daratumumab and hyaluronidase, to monotherapy after at least four prior lines [2]. Elranatamab (Elrexfio) and linvoseltamab (LYNOZYFIC) are each labeled after at least four prior lines under accelerated approval [3][4]. Belantamab mafodotin (BLENREP), a BCMA-directed antibody-drug conjugate, is labeled with bortezomib and dexamethasone after at least two prior lines [5]. A BCMA-directed CAR-T, ciltacabtagene autoleucel (CARVYKTI), is also FDA-indicated for the disease [6].

The efficacy argument for BCMA engagement is settled by those approvals. Etentamig's room to compete sits in where it can be given and how simply, which is exactly where AbbVie has aimed its message.

The trials behind the filing

Two Phase 3 studies anchor the program. NCT06158841 tests etentamig monotherapy against standard available therapies in 421 participants and was active but no longer recruiting as of its 27 August 2026 record [7]. NCT07728188 pairs etentamig with pomalidomide against standard available therapies in 520 participants and was not yet open as of its 27 July 2026 record [8]. Earlier-phase work continues, including combinations with iberdomide (NCT06896916, recruiting) and a subcutaneous formulation in Phase 1 (NCT06223516, active, no longer recruiting) [9][10]. The subcutaneous option is a study, not the BLA: this application is for the intravenous engager [1][10].

What to watch next

The hard signal to watch is FDA acceptance. The agency typically decides whether to file a BLA within about 60 days of submission, which points to roughly late December 2026 (Prognyx estimate). After filing, a standard review runs about ten months, so a decision would land roughly in late 2027, Prognyx's derived range assuming standard review and on-time filing. AbbVie has not disclosed whether it is seeking priority review in the retrieved announcement; a priority designation would compress the decision toward roughly mid-2027. Treat both as Prognyx ranges built on the submission date, not FDA-confirmed targets.

The now-what

For an operator with a BCMA or myeloma asset, three moves are on the table. Lean into administration: outpatient feasibility, step-up simplicity and site of care are where etentamig has staked its claim [1], and a program that depends on academic-center infusion loses ground if etentamig clears. Reassess line positioning: the marketed engagers cluster at four or more prior lines, except teclistamab's earlier combination [2][3][4], so a new entrant's value turns on how credibly it moves earlier. Or hold: the pivotal efficacy readout is not confirmed from a primary source yet, and FDA acceptance will tell you more than any headline.

What Prognyx could not verify

Several September 2026 trade headlines (CancerNetwork, OncLive, Targeted Oncology, Investing News Network, The Pharma Letter, Oncodaily) reported that a Phase 3 trial named CERVINO met dual primary endpoints of overall response rate and progression-free survival. Prognyx could not confirm this from a primary AbbVie release or an SEC filing, and the ClinicalTrials.gov records retrieved neither carry those results nor identify which trial corresponds to CERVINO. AbbVie's announcement did not disclose a target FDA action date or review designation in the text Prognyx retrieved.

Verdict: threat to competing BCMA bispecific programs is moderate and rising, with the next decisive signal, FDA acceptance, due by roughly late December 2026 on Prognyx's estimate.

Questions this briefing answers

What did AbbVie file, and when?

AbbVie submitted a Biologics License Application to the U.S. FDA on 27 October 2026 for etentamig, its intravenous second-generation BCMA x CD3 bispecific antibody T-cell engager, in adults with relapsed or refractory multiple myeloma [1].

Has the FDA set a decision date?

AbbVie's announcement did not disclose a target action date or review designation. A standard BLA review would place a decision roughly in late 2027, following an expected filing decision around late December 2026; both are Prognyx estimates built on the submission date, not FDA-confirmed targets.

Sources: every claim traces to the primary record

  1. AbbVie newsroom, BLA submission for etentamig
  2. DailyMed FDA label, TECVAYLI (teclistamab-cqyv)
  3. DailyMed FDA label, Elrexfio (elranatamab-bcmm)
  4. DailyMed FDA label, LYNOZYFIC (linvoseltamab-gcpt)
  5. DailyMed FDA label, BLENREP (belantamab mafodotin)
  6. DailyMed FDA label, CARVYKTI (ciltacabtagene autoleucel)
  7. ClinicalTrials.gov NCT06158841
  8. ClinicalTrials.gov NCT07728188
  9. ClinicalTrials.gov NCT06896916
  10. ClinicalTrials.gov NCT06223516

How this briefing was produced: Drafted and audited by the Prognyx engine against the primary sources cited above, then published automatically for clearing the audit threshold set by Rali Filali. Below that threshold, a briefing is not published. The full method.

Want this on your pipeline?
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.

Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.